- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Journal Introduction
- Editorial Board
- Youth Editorial Board
- Editorial Board Charter
- Subscriptions
- Archive
- Current Issue
- Past Issues
- Priority Publication
- Virtual Collection
- Recommended Articles
- Submission
- Submission Process
- Submission Guidelines
- Download
- Contact us
- For Reviewers
- Guidelines for Reviewers
- Peer Reviewed Policies
- Statement and Policies
- Ethics and Malpractice
- Research Ethics Policies
- Repetition Detection
- Corrections and Retractions
- Editorial Policies
- Open Access Statement
- Website Responsibility
Development and application of drug-induced liver injury surveillance and assessment system
- ZHONGGUO YAOFANG Vol. 34, Issue 19, Pages: 2409-2413(2023)
- 作者机构：
1.清华大学附属北京清华长庚医院/清华大学临床医学院药学部，北京 102218
2.清华大学电子工程系，北京 100084
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.19.18
CLC： R975+.5Received：28 March 2023，
Revised：2023-08-18，
Accepted：18 August 2023，
Published：15 October 2023
- 稿件说明：
移动端阅览
艾超,冀召帅,张雅鑫,等.药物性肝损伤自动监测与评估系统的研发与应用[J].中国药房,2023,34(19):2409-2413.
AI Chao,JI Zhaoshuai,ZHANG Yaxin,et al.Development and application of drug-induced liver injury surveillance and assessment system[J].ZHONGGUO YAOFANG,2023,34(19):2409-2413.
艾超,冀召帅,张雅鑫,等.药物性肝损伤自动监测与评估系统的研发与应用[J].中国药房,2023,34(19):2409-2413. DOI： 10.6039/j.issn.1001-0408.2023.19.18.
AI Chao,JI Zhaoshuai,ZHANG Yaxin,et al.Development and application of drug-induced liver injury surveillance and assessment system[J].ZHONGGUO YAOFANG,2023,34(19):2409-2413. DOI： 10.6039/j.issn.1001-0408.2023.19.18.
摘要
目的
2
建立药物性肝损伤（DILI）自动监测与评估系统（DILI-SAS），提升临床DILI的诊断效率。
方法
2
利用自然语言处理技术对全部住院病历数据进行挖掘和利用，并结合Roussel Uclaf因果关系评价法（RUCAM）构建DILI-SAS。对2022年8月－2023年1月期间在清华大学附属北京清华长庚医院住院的19 445例患者病历进行检测，验证系统性能并人工分析DILI患者基本资料及第一怀疑药物分布情况。
结果
2
DILI-SAS整体准确率为91.95%，召回率为93.20%；共监测出75例DILI病例，DILI发生率为385.70/10万人；通过人机耦合的方式开展DILI监测效率比人工独立监测约提高了60倍；75例DILI中主要以男性（61.33%）、60岁以上（56.00%）患者为主，肝损伤临床分型主要是肝细胞损伤型（69.33%），潜伏期主要集中在用药后5～90 d（62.67%），RUCAM评分在3～5分之间最多（66.67%）；第一怀疑药物的药理分布主要为二氢吡啶类、羟甲基戊二酸单酰辅酶A还原酶抑制剂、质子泵抑制剂等，具体药物有阿托伐他汀、奥美拉唑、头孢曲松、甲硝唑等。
结论
2
建立的DILI-SAS在保障系统准确度的基础上，能提升DILI评价时效性，可为临床DILI的早期识别、诊断、评价提供解决方案。
Abstract
OBJECTIVE
2
To establish the drug-induced liver injury （DILI） surveillance and assessment system （DILI-SAS）， and to improve the diagnostic efficiency of clinical DILI.
METHODS
2
The DILI-SAS was constructed by using natural language processing technology to mine and utilize all inpatient medical record data， and combined with Roussel Uclaf causality assessment method （RUCAM）. The medical records of 19 445 hospitalized patients from August 2022 to January 2023 were detected to verify the performance of the system and manually analyze the basic data of patients with DILI and the distribution of the first suspected drugs.
RESULTS
2
The overall accuracy rate of the DILI-SAS system was 91.95%， and the recall rate was 93.20%. Seventy-five DILI cases were detected， and the DILI incidence rate was 385.70/100 000 people. The efficiency of DILI monitoring by human-computer coupling was increased by about 60 times of manual monitoring； males （61.33%） and patients over 60 years old （56.00%） were the most common in the 75 cases of DILI. The clinical type of liver injury was hepatocyte injury （69.33%）， the incubation period was mainly 5-90 days after treatment （62.67%）， and the RUCAM score between 3 and 5 was the most common （66.67%）； pharmacological distribution of the first suspected drugs was mainly dihydropyridines， HMG CoA reductase inhibitors， proton pump inhibitors， etc. The specific drugs were atorvastatin， omeprazole， ceftriaxone， metronidazole and other drugs.
CONCLUSIONS
2
The establishment of DILI-SAS can improve the evaluation efficiency on the basis of ensuring the accuracy degree， and provide a solution for the early identification， diagnosis and evaluation of clinical DILI.
关键词
Keywords
references
XIAO X H ， TANG J Y ， MAO Y M ， et al . Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury issued by China Food and Drug Administration [J ] . Acta Pharm Sin B ， 2019 ， 9 （ 3 ）： 648 - 658 .
茅益民 . 加强基于大数据的药物性肝损伤的科学研究和监管 [J ] . 临床肝胆病杂志 ， 2018 ， 34 （ 6 ）： 1166 - 1168 .
MAO Y M . Strengthening the scientific research and supervision of drug-induced liver injury based on big data [J ] . J Clin Hepatol ， 2018 ， 34 （ 6 ）： 1166 - 1168 .
于乐成 ， 茅益民 ， 陈成伟 . 药物性肝损伤诊治指南 [J ] . 肝脏 ， 2015 ， 20 （ 10 ）： 750 - 767 .
YU L C ， MAO Y M ， CHEN C W . Guidelines for the ma- nagement of drug-induced liver injury [J ] . Chin Hepatol ， 2015 ， 20 （ 10 ）： 750 - 767 .
SHEN T ， LIU Y ， SHANG J ， et al . Incidence and etiology of drug-induced liver injury in mainland China [J ] . Gastroenterology ， 2019 ， 156 （ 8 ）： 2230 - 2241 .
肖小河 . 医药结合，助力药物性肝损伤精准防控 [J ] . 临床肝胆病杂志 ， 2020 ， 36 （ 3 ）： 489 - 490 .
XIAO X H . Combination of medicine and pharmacy assists for precise prevention and control of drug-induced liver injury [J ] . J Clin Hepatol ， 2020 ， 36 （ 3 ）： 489 - 490 .
WU J ， LIU X E ， ZHANG X ， et al . Master clinical medical knowledge at certificated-doctor-level with deep learning model [J ] . Nat Commun ， 2018 ， 9 （ 1 ）： 4352 .
李强 ， 周佳雯 ， 崔好胜 ， 等 . 基于人工智能的病案首页诊断漏写检查技术应用研究 [J ] . 中国数字医学 ， 2022 ， 17 （ 6 ）： 56 - 61 .
LI Q ， ZHOU J W ， CUI H S . Research and application of the word missing checking technology for the first page diagnosis of medical records based on artificial intelligence [J ] . China Digit Med ， 2022 ， 17 （ 6 ）： 56 - 61 .
DANAN G ， TESCHKE R . Roussel Uclaf causality assessment method for drug-induced liver injury：present and future [J ] . Front Pharmacol ， 2019 ， 10 ： 853 .
中华医学会 ， 中华医学会杂志社 ， 中华医学会消化病学分会 ， 等 . 药物性肝损伤基层诊疗指南：2019年 [J ] . 中华全科医师杂志 ， 2020 ， 19 （ 10 ）： 868 - 875 .
Chinese Medical Association ， Chinese Medical Journals Publishing House ， Chinese Society of Gastroenterology ， et al . Guideline for primary care of drug-induced liver injury：2019 [J ] . Chin J General Practitioners ， 2020 ， 19 （ 10 ）： 868 - 875 .
DEVARBHAVI H ， AITHAL G ， TREEPRASERTSUK S ， et al . Drug-induced liver injury：Asia Pacific Association of study of liver consensus guidelines [J ] . Hepatol Int ， 2021 ， 15 （ 2 ）： 258 - 282 .
中华中医药学会肝胆病分会 ， 中华中医药学会中成药分会 . 中草药相关肝损伤临床诊疗指南 [J ] . 临床肝胆病杂志 ， 2016 ， 32 （ 5 ）： 835 - 843 .
Branch of Hepatobiliary Diseases of China Association of Chinese Medicine ， Branch of Chinese Patent Medicine of China Association of Chinese Medicine . Guideline for diagnosis and treatment of herb-induced liver injury [J ] . J Clin Hepatol ， 2016 ， 32 （ 5 ）： 835 - 843 .
CHALASANI N P ， HAYASHI P H ， BONKOVSKY H L ， et al . ACG clinical guideline：the diagnosis and management of idiosyncratic drug-induced liver injury [J ] . Am J Gastroenterol ， 2014 ， 109 （ 7 ）： 950 - 967 .
何婷婷 ， 梁庆升 ， 王丽苹 ， 等 . 整合证据链、Roussel Uclaf因果关系评价法、结构化专家观点程序对药物性肝损伤的诊断效用分析 [J ] . 临床肝胆病杂志 ， 2022 ， 38 （ 1 ）： 141 - 147 .
HE T T ， LIANG Q S ， WANG L P ， et al . Diagnostic values of integrated evidence chain，Roussel Uclaf causality assessment method，and structured expert opinion process method for drug-induced liver injury [J ] . J Clin Hepatol ， 2022 ， 38 （ 1 ）： 141 - 147 .
袁琳娜 ， 那恒彬 ， 李武 . 《2021年亚太肝病学会共识指南：药物性肝损伤》摘译 [J ] . 临床肝胆病杂志 ， 2021 ， 37 （ 6 ）： 1291 - 1294 .
YUAN L N ， NA H B ， LI W . An excerpt of Drug-induced liver injury：Asia Pacific Association of Study of Liver Consensus Guidelines （ 2021 ） [J ] . J Clin Hepatol ， 2021 ， 37 （ 6 ）： 1291 - 1294 .
0
Views
212
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.